.

Deeper Knowledge, Faster

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Federal Trade Commission
Dow
McKinsey
Farmers Insurance
UBS
Baxter
Cantor Fitzgerald
Boehringer Ingelheim
Moodys
McKesson

Generated: December 17, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 205388

« Back to Dashboard

NDA 205388 describes OMIDRIA, which is a drug marketed by Omeros and is included in one NDA. It is available from one supplier. There are six patents protecting this drug and one Paragraph IV challenge. Additional details are available on the OMIDRIA profile page.

The generic ingredient in OMIDRIA is ketorolac tromethamine; phenylephrine hydrochloride. There are eighteen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the ketorolac tromethamine; phenylephrine hydrochloride profile page.

Summary for 205388

Tradename:1
Applicant:1
Ingredient:1
Patents:6
Formulation / Manufacturing:see details

Pharmacology for NDA: 205388

Suppliers and Packaging for NDA: 205388

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
OMIDRIA ketorolac tromethamine; phenylephrine hydrochloride SOLUTION;IRRIGATION 205388 NDA Omeros Corporation 62225-600 62225-600-10 10 VIAL in 1 CARTON (62225-600-10) > 4 mL in 1 VIAL
OMIDRIA ketorolac tromethamine; phenylephrine hydrochloride SOLUTION;IRRIGATION 205388 NDA Omeros Corporation 62225-600 62225-600-00 1 VIAL in 1 CARTON (62225-600-00) > 4 mL in 1 VIAL

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:SOLUTION;IRRIGATIONStrengthEQ 0.3% BASE;EQ 1% BASE
Approval Date:May 30, 2014TE:RLD:Yes
Regulatory Exclusivity Expiration:May 30, 2017
Regulatory Exclusivity Use:NEW PRODUCT
Patent:► SubscribePatent Expiration:Jul 30, 2023Product Flag?Substance Flag?Delist Request?
Patented Use:MAINTAINING PUPIL SIZE BY PREVENTING INTRAOPERATIVE MIOSIS AND REDUCING POSTOPERATIVE OCULAR PAIN
Patent:► SubscribePatent Expiration:Jul 30, 2023Product Flag?YSubstance Flag?Delist Request?


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Baxter
Federal Trade Commission
Queensland Health
US Department of Justice
UBS
McKesson
Dow
Argus Health
Cantor Fitzgerald
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot